Eli Lilly Gets $275 Million U.S. Pact for Covid-19 Antibody Drug
June 29 2022 - 7:42AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. on Wednesday said it agreed to supply an
additional 150,000 doses of its Covid-19 antibody drug bebtelovimab
to the U.S. government for about $275 million.
The Indianapolis drugmaker said the new order should let the
government meet current demand through late August.
The Food and Drug Administration in February granted
emergency-use authorization to bebtelovimab, which retains
effectiveness against the Omicron variant of Covid-19, filling a
void after authorities stopped distributing some older antibody
drugs that lost effectiveness against the strain.
Eli Lilly on Wednesday said bebtelovimab continues to maintain
neutralization activity against the most common and fastest growing
Omicron variants in the U.S., along with all known variants of
interest and concern.
Eli Lilly in February said that it would supply up to 600,000
doses of bebtelovimab to the government for at least $720 million,
and that the government had an option to buy a further 500,000
doses by the end of July. The company on Wednesday said an option
for an additional 350,000 doses to be exercised by Sept. 14 remains
in the agreement.
-Peter Loftus contributed to this article.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 29, 2022 07:27 ET (11:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024